Literature DB >> 8866188

Therapeutic drug monitoring of the antimycobacterial drugs.

C A Peloquin1.   

Abstract

Because MDR tuberculosis and MAC are difficult to treat, TDM with the antimycobacterial drugs has become the standard of practice at NJC. By combining specific and sensitive assays, carefully collected samples, and clinical expertise, we are able to control and optimize antimycobacterial drug therapy. We continue to refine our approach with ongoing pharmacokinetic and pharmacodynamic research. Although such an array of services is not typical of most nonspecialized institutions, it is possible to follow the techniques described and to access our assay services. Furthermore, the elements of a good TDM service described can be applied to the TDM for any other disease state.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866188

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  6 in total

Review 1.  The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.

Authors:  G W Amsden; C A Peloquin; S E Berning
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Role of embB in natural and acquired resistance to ethambutol in mycobacteria.

Authors:  F Alcaide; G E Pfyffer; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

3.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

4.  Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.

Authors:  John E Conte; Jeffrey A Golden; Juliana E Kipps; Emil T Lin; Elisabeth Zurlinden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin.

Authors:  Aliasgar Kundawala; Vishnu Patel; Harsha Patel; Dhaglaram Choudhary
Journal:  Sci Pharm       Date:  2014-07-23

6.  Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease.

Authors:  Xuanyou Jin; Jaeseong Oh; Joo-Youn Cho; SeungHwan Lee; Su-Jin Rhee
Journal:  Antibiotics (Basel)       Date:  2020-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.